News for RXDX Stock

Cellino Appoints Chris Gibson to Board of Directors Merck Completes Acquisition of Prometheus Biosciences, Inc. Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO) Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress Prometheus Biosciences to Participate at November Healthcare Conferences Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052 Prometheus Biosciences to Participate at September Healthcare Conferences Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022 Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies Prometheus Biosciences to Participate at the Jefferies Healthcare Conference Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress Prometheus Biosciences to Present at Upcoming Investor Conferences Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC) Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021 Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering